Drug Development platforms for Aymotrophic Lateral Sclerosis

---

• Our mission is to develop novel therapeutic agents for the treatment of patients suffering form neurodegenerative diseases. The initial platform focuses on ALS by leveraging our 20 years of basic neuroscience and pre-clinical research in the field. 

• Protein abnormalities and clumping (misfolding, oligomerization, and aggregation) are common in neurodegenerative diseases and there is nothing that exists to prevent that. We are focused on developing a solution for this significant problem. Our pre-clinical work is aimed at discovering an effective anti-aggregating class of drugs for this purpose.

•  In the US, it is estimated that 930,000 people will be diagnosed with Parkinson's by 2020 and this will grow to 1.24 million by 2030. The US anti-Parkinson's drug market is predicted to grow from $1.1 billion in 2017 to $1.4 billion in 2020.

• RockGen is focused on disorders involved in progressive loss of structure or function of neurons (neurodegenerative disease) including Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other dementias, Parkinson's disease, Motor neuron diseases, Huntington's disease

Seeking Business Partnership Opportunities

•  Neurodegenerative disease patients don’t have effective therapy now and the number of patients is increasing exponentially.